Biotech 2011-Life Sciences

Looking Back to See Ahead

Product Code BUR00001
Publication Date April 2011
Publisher Burrill
Product Type Report
Pages 370
ISBN Number not applicable
Change currency
PDF £140.00 €169 $221 BUY >
PRINT £160 €193 $253 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Biotech 2011-Life Sciences

Looking Back to See Ahead

Considered required reading by top executives in the life science industry, this book is an invaluable, one-stop resource to make sense of the changing landscape.

In Looking Back to See Ahead, you will discover:

  • How pharmaceutical companies are reinventing themselves to address their pipeline problems and the competition from generics
  • New strategies investors are pursuing to improve their returns
  • How the convergence of wireless, mobile, and Internet technologies is making personalized medicine a reality
  • The global interplay between science, business, regulatory, reimbursement, politics and policy

Comprehensive, unparalleled coverage of key trends makes Looking Back to See Ahead a critical resource for senior executives, as well as business development, sales, investment, legal, economic development, and other professionals who support the industry, to stay competitive in a fast-moving world.

Contents

  • Introduction: Looking Back
    • Chapter 2: Reinventing an Industry
    • Chapter 3: Mapping the Future
    • Chapter 4: Mending a Broken System
    • Chapter 5: Seeking Balance
    • Chapter 6: Emerging Markets Fuel Growth
    • Chapter 7: Addressing Global Challenges
    • Chapter 8: Shifting Risk
    • Chapter 9: Playing by New Rules
    • Chapter 10: Seeing Ahead
  • List of charts:
  • Chapter 1: LOOKING BACK
    • 1.1 Biotech's Boom and Bust Cycles
    • 1.2 Industry Market Capitalization, 1980-201
    • 1.3 Evolution of Biotech's Business Model
    • 1.4 Top Ten Selling Products in 2016; Worldwide Annual Sales
  • Chapter 2: REINVENTING AN INDUSTRY
    • 2.1 Value Creation - Genentech vs. Pfizer, 1999-2008
    • 2.2 Drug Development: A Slow, Expensive,and Risky Endeavor
    • 2.3 Selected Drug Patents Expiring, 2010-2012
    • 2.4 Impact of Competition from Generics on Big Pharma Revenues
    • 2.5 Big Pharma's Sourcing of External Products Will Grow
    • 2.6 Divergent Rates of Growth of Pharmaceutical Markets
    • 2.7 Pharma Innovation Gap
    • 2.8 Drug Development Cost Estimate Curve
    • 2.9 A Changed Environment: Substantially Reduced Return Metrics
    • 2.10 Worldwide R&D Spending Growth
    • 2.11 Large vs. Small Companies' Innovation
    • 2.12 Projected Costs of Alzheimer's Treatment
    • 2.13 Sanofi-Aventis Moves in All Directions to Replace Revenues
  • Chapter 3: MAPPING THE FUTURE
    • 3.1 The Burrill Personalized Medicine Index, 2010
    • 3.2 The Burrill Diagnostics Index, 2010
    • 3.3 Selected Public-Private Partnerships in Diagnostics, 2010
    • 3.4 Select Partnering Deals in Personalized Medicine in 2010
    • 3.5 The Cost of Sequencing
    • 3.6 Select Venture Financings in 2010 in Personalized Medicine
    • 3.7 Select Personalized Medicine M&A in 2010
    • 3.8 Digital Health Venture Financings in 2010
    • 3.9 Remote Monitoring Savings
    • 3.10 Mobile Phones Proliferate
  • Chapter 4: MENDING A BROKEN SYSTEM
    • 4.1 Actual and Projected U.S. Healthcare Spending, Selected Years
    • 4.2 Healthcare Reform to Raise National Health Expenditure
    • 4.3 Life Expectancy vs. Healthcare Spending in OECD Countries
    • 4.4 Healthcare Systems Around the World Struggle with Cost, Access, and Delivery
    • 4.5 The U.S. Healthcare Dollar-Where It Comes From
    • 4.6 The U.S. Healthcare Dollar-Where It Goes
    • 4.7 The Cost of Chronic Disease
    • 4.8 Comparative Costs of Medical Procedures in the U.S. and Abroad
    • 4.9 Comparative Effectiveness Spending
  • Chapter 5: SEEKING BALANCE
    • 5.1 FDA and Headcount Growth
    • 5.2 U.S. Food and Drug Administration New Drug Approvals in 2010
    • 5.3 User Fees, New Drug and Biologics Applications Growth
    • 5.4 Number of Industry Settlements, by Year
    • 5.5 Patent Expiration of Biologics
    • 5.6 Potential Biosimilars in Europe
    • 5.7 Biologics Facing Loss of Exclusivity in the United States
  • Chapter 6: EMERGING MARKETS FUEL GROWTH
    • 6.1 Global Pharmaceutical Sales by Region
    • 6.2 An Aging Population
    • 6.3 Pharmaceutical Sales Growth in Emerging Markets
    • 6.4 Medical Technology Innovation Scorecard
    • 6.5 Early-stage Entrepreneurial Activity vs. Venture Capital Investment As Percent of GDP
    • 6.6 Select Big Pharma Emerging Markets Deals in 2010
    • CANADA
      • 6.7 Market Cap of Canadian Biotech Companies
      • 6.8 Burrill Canadian Biotech Index
      • 6.9 Selected Canadian Biotech Financings, 2010
      • 6.10 Select Biotech Venture Capital Investments, 2010
      • 6.11 Performance of Canada's Leading Biotech Companies by Market Cap, 2010
      • 6.12 Select Canadian Partnering Activity, 2010
      • 6.13 Select Acquisitions of Canadian Companies, 2010
      • 6.14 Brazilian Life Sciences Companies by Sector
      • 6.15 Top 20 Pharmaceutical Companies in Brazil by 2009 Sales
      • 6.16 Brazilian Pharmaceutical Industry Sales
      • 6.17 Select Brazilian Acquisitions in 2010
      • 6.18 Select Brazilian Partnering Activity, 2010
    • CHILE
      • 6.19 Chilean Biotech Industry Snapshot
      • 6.20 Chilean Biotech by the Numbers
    • ARGENTINA
      • 6.21 Argentina's Biotech Industry by Sector
    • EUROPE
      • 6.22 European Venture Financings by Country
      • 6.23 Top European Public Pharmaceutical Companies
      • 6.24 Top European Public Biotech Companies
      • 6.25 European Union Companies Cash on Runway, 2010
      • 6.26 Select European Partnering Activity, 2010
      • 6.27 Select European M&A, 2010
      • 6.28 Select European Public Financings, 2010
      • 6.29 European Venture Financings, 2010
    • NORDIC
      • 6.30 Nordic Life Sciences at a Glance
      • 6.31 Denmark's Drug Development Pipeline
      • 6.32 Select Nordic Financings, 2010
      • 6.33 Sweden's New Drug Development Pipeline
    • RUSSIA
      • 6.34 Russia's Biopharmaceutical Sector
      • 6.35 Top 20 Pharmaceutical Manufacturers by Sales
      • 6.36 Select Russian Deals in 2010
    • ISRAEL
      • 6.37 Israeli Biotech R&D Financing in 2007
      • 6.38 Israeli Biomed Index
      • 6.39 Select Israeli M&A, 2010
      • 6.40 Select Financings of Israeli Companies in 2010
      • 6.41 Select Israeli Partnering Deals, 2010
    • MIDDLE EAST
      • 6.42 United Arab Emirates at a Glance
      • 6.43 Select Middle Eastern Deals in 2010
      • 6.44 Middle East Drug Expenditures, Past and Projected
      • 6.45 Saudi Arabia at a Glance
      • 6.46 Qatar at a Glance
      • 6.47 Kuwait at a Glance
      • 6.48 Bahrain at a Glance
      • 6.49 Oman at a Glance
    • CHINA
      • 6.50 Growth of China's Healthcare Sector
      • 6.51 China IPO Activity, 2007-2010
      • 6.52 Chinese Life Sciences IPOs in 2010
      • 6.53 China VC Investments, 2008-2010
      • 6.54 China M&A Activity, 2008-2010
      • 6.55 China Partnering, 2010
      • 6.56 Chinese and Foreign Company Joint Ventures in 2010
      • 6.57 Select Chinese Public/Private Partnerships in 2010
      • 6.58 Select Chinese M&A in 2010 6.59 Select Chinese Licensing and Partnering Deals in 2010
    • TAIWAN
      • 6.60 Taiwan Biotech Industry Subsectors
      • 6.61 Market Segments of Newly Emerging Biotech Industry
      • 6.62 Private Investment in Biotech Industry
    • SOUTH KOREA
      • 6.63 Top Players in Korea's Pharmaceutical Market
      • 6.64 South Korean Life Sciences IPOs in 2010
      • 6.65 Select South Korean M&A in 2010
      • 6.66 Select South Korean Partnering and Licensing Deals in 2010
      • 6.67 South Korean Medical Device Market
      • 6.68 Green Investment in South Korea
    • JAPAN
      • 6.69 Japanese Pharma's Patent Cliff
      • 6.70 Western Acquisitions by Japanese Drug Makers
      • 6.71 Top Japanese Public Biotech Companies
      • 6.72 Top Japanese Public Pharmaceutical Companies
      • 6.73 Japanese Pharmaceutical Companies' Global Expansion
      • 6.74 Top Japanese Public Pharmaceutical Companies
      • 6.75 Select Japanese Pharmaceutical Licensing and Partnering Deals, 2010
    • INDIA
      • 6.76 Indian Healthcare Sectors Poised for Growth
      • 6.77 India's Top Ten Biopharma Companies by Revenue
      • 6.78 Biotech in India: Sectors by Percent of Industry
      • 6.79 Top Indian Drug Companies by Annual Generic
      • 6.80 Pharmaceutical Sales 6.80 Indian Pharmaceutical Industry Growth
      • 6.81 Pharma Looks to India: Select Partnering and Licensing Deals in 2010
      • 6.82 Select 2010 Indian Life Sciences M&A
    • MALAySIA
      • 6.83 National Biotechnology Policy Development Goals
      • 6.84 Select Malaysian Partnering Activities in 2010
      • 6.85 Malaysian Biotechnology Sector Overview
      • 6.86 Malaysian Biotechnology Statistics
    • SINGAPORE
      • 6.87 Select Singapore M&A in 2010
      • 6.88 Select Singapore Partnering Transactions in 2010
    • AUSTRALIA
      • 6.89 Commercialization Australian Grant Structure
      • 6.90 Australia's Life Sciences by Sector
      • 6.91 Top 10 Australian Biotech Companies (September 30, 2010)
      • 6.92 Select Financings of Australian Life Sciences Companies, 2010
      • 6.93 Select Australian Licensing and Partnering Deals, 2010
      • 6.94 Select Australian M&A in 2010
    • SOUTH AfRICA
      • 6.95 Select South African Deals in 2010
      • 6.96 South Africa's Biotechnology Sector
  • Chapter 7: ADDRESSING GLOBAL CHALLENGES
    • 7.1 World Poplation vs Arable Land Per Capita
    • 7. 2 Prices of Corn, Oil and Ethanol, 2010, USD M
    • 7. 3 Meat Consumption Follows Economic Growth
    • 7.4 Agricultural Production and Predicted Amount of Calories Needed in 2050
    • 7.5 How Fresh Water Is Used
    • 7. 6 Global Clean Energy Investment by Financing Type
    • 7.7 Renewable Energy Demand, 2010
    • 7.8 The Future of Non-Hydro Electricity Generation: Biomass 7.9 Global New Investment in Clean Energy, 2004-10
    • 7.10 Worldwide Mandates and Subsidies for Biofuels: Policy Status in Five Major World Regions
    • 7.11 Annual Global Support for Renewables
    • 7.12 Global Cleantech VC Investment
    • 7.13 Global Venture Investment in Biofuels
    • 7.14 U.S. Bio-Industrial Venture Investments in 2010
    • 7.15 Biofuels Goals
    • 7.16 Select Bio-Industrial M&A in 2010
    • 7.17 Share of Renewable Fuels in U.S. Energy Mix
    • 7.18 Revenue Potential of Biorefineries
    • 7.19 Industrial Biotech Sales
    • 7.20 Select Bioindustrial Partnering Deals in 2010
    • 7.21 Ag Adds to Chemical Companies' Bottom Line
    • 7.22 Four Largest Seed Companies's Share of Planted Acreage
    • 7.23 Cross-Licensing Deals
    • 7.24 Percent of GM Crops in the United States
    • 7.25 Genetically Modified Plants Worldwide
    • 7.26 Expansion in Value of GMO Market and GMO Acreage
    • 7.27 Burrill BioGreenTech Index
    • 7.28 Select Agricultural Biotechnology M&A in 2010
    • 7.29 Select Agricultural Biotechnology Partnering Deals in 2010
    • 7.30 Select Agricultural Biotechnology Venture Financings in 2010
  • Chapter 8: SHIFTING RISK
    • 8.1 2010 M&A Deal Volume
    • 8.2 Median M&A Premiums by Target Type
    • 8.3 Market Cap of Active Pharmaceutical Acquirers, 10-Year Range
    • 8.4 2010 M&A Transactions by Value Range
    • 8.5 2010 M&A Deals by Latest Stage of Product Development
    • 8.6 2010 M&A Transactions by Therapeutic Area
    • 8.7 M&A Transactions with Earnouts by Deal Size
    • 8.8 Partnering Deals by Big Pharma
    • 8.9 Industry-Wide Alliances -Numbers and Average Deal Values
    • 8.10 Industry-Wide Alliances - Numbers and Total Deal Values
    • 8.11 2010 Partnering Deals by Latest Stage of Product Development
    • 8.12 2010 Partnering Transactions by Primary Therapeutic Area
    • 8.13 Major Acquisitions by Big Pharma 1986-2010
    • 8.14 Average Up-Front Payments by Stage of Development
    • 8.15 Licensing Deals and the Territories They Include
    • 8.16 Terminated Deals in 2010
  • Chapter 9: PLAYING BY NEW RULES
    • 9.1 U.S. Biotech Financings, 2006-2010 (USD B)
    • 9.2 2010 Top Debt Issues
    • 9.3 2010 Top Follow-Ons
    • 9.4 2010 Top PIPEs
    • 9.5 2010 Top Grants
    • 9.6 2010 Top Contracts
    • 9.7 Top Venture Fundings in 2010, by Category
    • 9.8 Corporate Venture Investments, 1997-2010
    • 9.9 Market Cap Segmented, 2010 (USD)
    • 9.10 Biggest Advancers and Decliners in 2010
    • 9.11 Capital Raised by U.S. Biotechs, 2010
    • 9.12 Burrill Select Index, 1-Year, 2010
    • 9.13 Burrill Select Index, 5-Year, 2010
    • 9.14 Burrill Large-, Mid-, and Small-Cap Indices 1-Year, 2010
    • 9.15 Burrill Large-, Mid-, and Small-Cap Indices 5-Year, 2010
    • 9.16 Life Sciences IPOs on U.S. Exchanges
    • 9.17 Committed Equity Financing Facilities Announced in 2010
    • 9.18 Therapeutic Discovery Project Program by State
    • 9.19 Historical U.S. IPOs
    • 9.20 The IPO Class of 2000 - Where Are They Now?
    • 9.21 U.S. Public Company Reconciliation
    • 9.22 Public Companies' Performance, 2001- 2010